MIRA INFORM REPORT

 

 

Report No. :

301481

Report Date :

05.01.2015

 

IDENTIFICATION DETAILS

 

Name :

POLYPEPTIDE LABORATORIES PRIVATE LIMITED

 

 

Registered Office :

K-28, Additional MIDC Area, Anand Nagar, Ambernath (East), Ambernath, Thane – 421506, Maharashtra

 

 

Country :

India

 

 

Financials (as on) :

31.03.2013

 

 

Date of Incorporation :

06.02.2001

 

 

Com. Reg. No.:

11-130734

 

 

Capital Investment / Paid-up Capital :

Rs. 603.789 Millions

 

 

CIN No.:

[Company Identification No.]

U51397MH2001PTC130734

 

 

IEC No.:

Not Available

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

Not Available

 

 

PAN No.:

[Permanent Account No.]

AAGCP2809P

 

 

Legal Form :

Private Limited Liability Company.

 

 

Line of Business :

Supplier of injectable insulins, custom peptides, generic peptides, oxytocin, calcitonin and octreotide medicines.

 

 

No. of Employees :

Information declined by the management.

 

 

RATING & COMMENTS

 

MIRA’s Rating :

B (30)

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

 

 

Payment Behaviour :

Slow But Correct

 

 

Litigation :

Clear

 

 

Comments :

Subject is an established company having moderate track record.

 

The management has failed to file its financial record with government department for the year 2014.

 

As per available financial record of 2013, the rating takes into consideration company’s moderate financial risk profile and accumulated losses incurred by the company.

 

However, trade relations are fair. Business is active. Payments are reported to be slow but correct.

 

The company can be considered for business dealing with some caution.

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

 

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2014.

 

 

INFORMATION DENIED

 

Management non co-operative (Tel No.: 91-125-3981915)

 

 

LOCATIONS

 

Registered Office :

K-28, Additional MIDC Area, Anand Nagar, Ambernath (East), Ambernath, Thane – 421506, Maharashtra, India

Tel. No.:

91-125-3981915/915

Fax No.:

Not Available

E-Mail :

sudhir.navangul@polypeptideindia.com

 

 

DIRECTORS

 

AS ON 30.09.2013

 

Name :

Mr. Ashok Dattatraya Alate

Designation :

Director

Address :

53, Atharva, Mumbai – 400088, Maharashtra, India

Date of Birth/Age :

12.04.1952

Date of Appointment :

06.02.2001

PAN No.:

ABSPA8487E

DIN No.:

00491315

 

 

Name :

Jan Ake Froborg

Designation :

Director

Address :

Sankt Mansgatan 9B, SE-22229 Lund, Lund SE22229

Date of Appointment :

01.08.2003

DIN No.:

02519875

 

 

Name :

Lars Goran Peter Nilsson

Designation :

Director

Address :

Sodergatan 58,SE-27434, Skurup 27434

Date of Birth/Age :

21.02.1950

Date of Appointment :

01.04.2008

DIN No.:

02520301

 

 

Name :

Alain Scarso

Designation :

Director

Address :

Skogsmataregatan 48, 218 38 Bunkeflostrand, Bunkeflo 21838

Date of Appointment :

30.09.2011

DIN No.:

03428279

 

 

Name :

Jane Salik

Designation :

Director

Address :

25928 Richville Dr. Torrance, Torrance CA90505

Date of Appointment :

30.09.2011

DIN No.:

03450265

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

AS ON 30.09.2013

 

Names of Equity Shareholder

 

No. of Shares

 

Polypeptide Laboratories B. V., Netherlands

 

35761709

Ashok Alate, Mumbai

 

1

Total

 

35761710

 

 

Names of Preference Shareholder

 

No. of Shares

 

Polypeptide Laboratories B. V., Netherlands

 

24617170

 

 

 

Total

 

 

24617170

 

AS ON 30.09.2013

 

Equity Share Break up (Percentage of Total Equity)

 

Category

Percentage of Holding

Foreign holdings( Foreign institutional investor(s), Foreign companie(s) Foreign financial institution(s), Non-resident Indian(s) or Overseas Corporate bodies or Others

100.00

Total

100.00

 

 

 

BUSINESS DETAILS

 

Line of Business :

Supplier of injectable insulins, custom peptides, generic peptides, oxytocin, calcitonin and octreotide medicines.

 

 

Products :

Not Available

 

 

Brand Names :

Not Available

 

 

Agencies Held :

Not Available

 

 

Exports :

Not Divulged

 

 

Imports :

Not Divulged

 

 

Terms :

Not Available

 

 

GENERAL INFORMATION

 

Suppliers :

Reference :

Not Divulged

Name of the Person :

Not Divulged

Contact No.:

Not Divulged

Since How Long Known :

Not Divulged

Experience :

Not Divulged

Maximum Limit Dealt :

Not Divulged

 

 

Customers :

Reference :

Not Divulged

Name of the Person :

Not Divulged

Contact No.:

Not Divulged

Since How Long Known :

Not Divulged

Experience :

Not Divulged

Maximum Limit Dealt :

Not Divulged

 

 

No. of Employees :

Information declined by the management.

 

 

Bankers :

Banker Name

Not Divulged

Branch Address

Not Divulged

Person Name (With Designation)

Not Divulged

Contact Number

Not Divulged

Name of Account Holder

Not Divulged

Account Number

Not Divulged

Account Since (Date/Year of Account Opening)

Not Divulged

Average Balance Maintained (If Possible)

Not Divulged

Credit Facilities Enjoyed (If any)

Not Divulged

Account Operation

Not Divulged

Remarks (If any)

Not Divulged

 

 

Facilities :

SECURED LOANS

31.03.2013

(Rs. in Millions)

31.03.2012

(Rs. in Millions)

SHORT TERM BORROWINGS

 

 

Term loan from bank

64.769

1.316

 

 

 

Total

64.769

1.316

 

 

 

Auditors :

 

Name :

Yogesh Sovani and Associates

Chartered Accountants

Address :

1/101, Hans Apartments, Anton Francis Road, Charai, Thane, Mumbai – 400601, Maharashtra, India

PAN No.:

ACEPS2656Q

 

 

Memberships :

Not Available

 

 

Collaborators :

Not Available

 

 

Holding Company :

  • Polypeptide Laboratories BV- Netherlands
  • Polypeptide Laboratories Holding AB Group Company

 

 

Related Party :

  • Polypeptide Laboratories (Sweden) AB Group Company
  • Polypeptide Laboratories AS- Denmark Group Company
  • Polypeptide Laboratories INC- USA Group Company
  • Polypeptide Laboratories San Diago Group Company

 

 

CAPITAL STRUCTURE

 

AS ON 30.09.2013

 

Authorised Capital :

No. of Shares

Type

Value

Amount

40,000,000

Equity Shares

Rs. 10/- each

Rs. 400.000 Millions

25,000,000

Preference Shares

Rs. 10/- each

Rs. 250.000 Millions

 

 

 

 

 

Total

 

Rs. 650.000 Millions

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

35,761,710

Equity Shares

Rs. 10/- each

Rs. 357.617 Millions

24,617,170

Preference Shares

Rs. 10/- each

Rs. 246.172 Millions

 

 

 

 

 

Total

 

Rs. 603.789 Millions

 

 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2013

31.03.2012

31.03.2011

I.              EQUITY AND LIABILITIES

 

 

 

(1)Shareholders' Funds

 

 

 

(a) Share Capital

603.789

603.789

316.870

(b) Reserves & Surplus

(10.825)

(181.227)

0.588

(c) Money received against share warrants

0.000

0.000

0.000

 

 

 

 

(2) Share Application money pending allotment

0.000

0.000

122.506

Total Shareholders’ Funds (1) + (2)

592.964

422.562

439.964

 

 

 

 

(3) Non-Current Liabilities

 

 

 

(a) long-term borrowings

759.000

744.700

631.987

(b) Deferred tax liabilities (Net)

6.362

1.053

0.000

(c) Other long term liabilities

0.000

0.000

0.000

(d) long-term provisions

4.282

4.276

3.245

Total Non-current Liabilities (3)

769.644

750.029

635.232

 

 

 

 

(4) Current Liabilities

 

 

 

(a) Short term borrowings

64.769

1.316

0.000

(b) Trade payables

16.658

22.642

30.786

(c) Other current liabilities

174.648

164.816

37.550

(d) Short-term provisions

21.178

3.401

1.388

Total Current Liabilities (4)

277.253

192.175

69.724

 

 

 

 

TOTAL

1639.861

1364.766

1144.920

 

 

 

 

II.            ASSETS

 

 

 

(1) Non-current assets

 

 

 

(a) Fixed Assets

 

 

 

(i) Tangible assets

1032.716

1094.113

338.381

(ii) Intangible Assets

0.000

0.000

0.000

(iii) Capital work-in-progress

8.939

32.743

708.505

(iv) Intangible assets under development

0.000

0.000

0.000

(b) Non-current Investments

0.000

0.000

0.000

(c) Deferred tax assets (net)

0.000

0.000

0.000

(d)  Long-term Loan and Advances

2.772

2.899

2.486

(e) Other Non-current assets

0.636

0.230

0.152

Total Non-Current Assets

1045.063

1129.985

1049.524

 

 

 

 

(2) Current assets

 

 

 

(a) Current investments

0.000

0.000

0.000

(b) Inventories

157.984

76.394

11.110

(c) Trade receivables

0.000

0.000

0.000

(d) Cash and cash equivalents

23.775

96.970

33.116

(e) Short-term loans and advances

53.388

61.417

51.170

(f) Other current assets

359.651

0.000

0.000

Total Current Assets

594.798

234.781

95.396

 

 

 

 

TOTAL

1639.861

1364.766

1144.920

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2013

31.03.2012

31.03.2011

 

SALES

 

 

 

 

 

TOTAL                                    

435.589

1.707

NA

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

TOTAL                                    

144.795

94.952

NA

 

 

 

 

 

 

PROFIT/ (LOSS)  BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION

290.794

(93.245)

NA

 

 

 

 

 

Less

FINANCIAL EXPENSES                                   

23.330

11.921

NA

 

 

 

 

 

 

PROFIT / (LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION

267.464

(105.166)

NA

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION                    

91.754

75.596

NA

 

 

 

 

 

 

PROFIT/ (LOSS)  BEFORE TAX 

175.710

(180.762)

NA

 

 

 

 

 

Less

TAX                                                                 

5.309

1.052

NA

 

 

 

 

 

 

PROFIT/ (LOSS)  AFTER TAX

170.401

(181.814)

0.261

 

 

 

 

 

 

IMPORTS

 

 

 

 

 

Raw Materials

96.108

0.159

NA

 

TOTAL IMPORTS

96.108

0.159

NA

 

 

 

 

 

 

Earnings / (Loss) Per Share (Rs.)

2.82

(3.01)

0.03

 

 

 

 

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2013

 

31.03.2012

31.03.2011

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

10.77

-13.57

0.00

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.30

-0.43

0.00

 

 

 

 

 

Debt Equity Ratio

(Total Liability/Networth)

 

1.39

1.77

1.44

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

2.15

1.22

1.37

 

 

FINANCIAL ANALYSIS

[all figures are in Rupees Millions]

 

DEBT EQUITY RATIO

 

Particular

31.03.2011

31.03.2012

31.03.2013

 

(Rs. In Millions)

(Rs. In Millions)

(Rs. In Millions)

Share Capital

316.870

603.789

603.789

Reserves & Surplus

0.588

-181.227

-10.825

Share Application money pending allotment

122.506

0.000

0.000

Net worth

439.964

422.562

592.964

 

 

 

 

long-term borrowings

631.987

744.700

759.000

Short term borrowings

0.000

1.316

64.769

Total borrowings

631.987

746.016

823.769

Debt/Equity ratio

1.436

1.765

1.389

 

 

 

YEAR-ON-YEAR GROWTH

 

Year on Year Growth

31.03.2012

31.03.2013

 

(Rs. In Millions)

(Rs. In Millions)

Total Income

1.707

435.589

 

 

25,417.809

 

 

 

NET PROFIT MARGIN

 

Net Profit Margin

31.03.2012

31.03.2013

 

(Rs. In Millions)

(Rs. In Millions)

Sales

1.707

435.589

Profit/ (Loss)

(181.814)

170.401

 

(10651.08%)

39.12%

 

 

 

LOCAL AGENCY FURTHER INFORMATION

 

NOTE: CURRENT MATURITY LONG TERM DEBT DETAILS ARE NOT AVAILABLE.

 

Sr. No.

Check List by Info Agents

Available in Report (Yes / No)

1]

Year of Establishment

Yes

2]

Locality of the firm

Yes

3]

Constitutions of the firm

Yes

4]

Premises details

No

5]

Type of Business

Yes

6]

Line of Business

Yes

7]

Promoter's background

Yes

8]

No. of employees

No

9]

Name of person contacted

No

10]

Designation of contact person

No

11]

Turnover of firm for last two years

Yes

12]

Profitability for last three years

Yes

13]

Reasons for variation <> 20%

-----------------

14]

Estimation for coming financial year

No

15]

Capital in the business

Yes

16]

Details of sister concerns

Yes

17]

Major suppliers

No

18]

Major customers

No

19]

Payments terms

No

20]

Export / Import details (if applicable)

No

21]

Market information

----------------

22]

Litigations that the firm / promoter involved in

---------------

23]

Banking Details

No

24]

Banking facility details

Yes

25]

Conduct of the banking account

----------------

26]

Buyer visit details

-----------------

27]

Financials, if provided

Yes

28]

Incorporation details, if applicable

Yes

29]

Last accounts filed at ROC

No

30]

Major Shareholders, if available

Yes

31]

Date of Birth of Proprietor/Partner/Director, if available

Yes

32]

PAN of Proprietor/Partner/Director, if available

Yes

33]

Voter ID No of Proprietor/Partner/Director, if available

No

34]

External Agency Rating, if available

No

 

 

INDEX OF CHARGES

 

NO CHARGES EXIST FOR THE COMPANY.

 

 

UNSECURED LOANS

 

PARTICULAR

31.03.2013

(Rs. in Millions)

31.03.2012

(Rs. in Millions)

LONG TERM BORROWINGS

 

 

Term Loan from others

759.000

744.700

 

 

 

Total

759.000

744.700

 

 

 

FIXED ASSETS

 

  • Land
  • Buildings
  • Factory Buildings
  • Plant and Equipments
  • Furniture and Fixture
  • Office Equipment
  • Computer Equipment

CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                           None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                        None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                        None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs. 63.29

UK Pound

1

Rs. 98.39

Euro

1

Rs. 76.31

 

 

INFORMATION DETAILS

 

Information Gathered by :

HET

 

 

Analysis Done by :

KAR

 

 

Report Prepared by :

JYO


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

3

PAID-UP CAPITAL

1~10

3

OPERATING SCALE

1~10

4

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

4

--PROFITABILIRY

1~10

4

--LIQUIDITY

1~10

3

--LEVERAGE

1~10

3

--RESERVES

1~10

3

--CREDIT LINES

1~10

3

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

YES

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

TOTAL

 

30

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.